Drug Profile
Autologous human adipose tissue derived bone tissue therapy - Bonus BioGroup
Alternative Names: Bone graft for maxillofacial applications - Bonus BioGroup; BonoFill; BonoFill-II; HATDCs - Bonus BioGroup; Human Adipose Tissue Derived Cells - Bonus BioGroupLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Bonus BioGroup
- Class Mesenchymal stem cell therapies; Tissue transplantation therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Bone disorders
Most Recent Events
- 23 Mar 2017 Phase-I/II development for Bone disorders (maxillofacial) is ongoing in Israel (Implant)
- 24 Jan 2017 BonusBio Group plans a phase I/II trial for Bone disorders in Israel (NCT03024008)
- 01 Jan 2017 BonusBio Group initiates enrolment in phase I/II for Bone disorders in Israel (NCT03024008)